Open an account

Cardiol Therapeutics

CRDL · TORONTO

$1.12−$0.03 (−2.61%)TodayMarket closed ·
Prev close $1.15

About CRDL

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company employs 18 full-time employees The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Employees
18
Headquarters
Oakville, Ontario
Listed
Dec 20, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
cardiolrx.com

CRDL key statistics

Market cap
197.88M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.53M
Volume
1.10M
Open price
$1.15
High today
$1.16
Low today
$1.11
52 Week high
$2.34
52 Week low
$0.88

Cardiol Therapeutics (CRDL) at a glance

Cardiol Therapeutics (CRDL) last traded at $1.12, with a market cap of 197.88M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.11 and $1.16. The current price is 1.4% above the day's low and 3.4% below its high.

Volume so far is 1.10M shares, below the average of 1.53M shares a day.

Over the past year Cardiol Therapeutics has ranged from $0.88 to $2.34, and now sits 16% of the way up that range.

Cardiol Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.1071.

The average analyst price target is $5.20, 364.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.20
Low
$4.95
Now
$1.12
High
$5.55

CRDL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 25.1% on average.

  1. Q3 FY24: reported -$0.18 per share against an estimate of -$0.1224
  2. Q4 FY24: reported -$0.09 per share against an estimate of -$0.1336
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.1428
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.1224
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.0918
  6. Q4 FY25: reported -$0.07 per share against an estimate of -$0.0816
  7. Q1 FY26: reported -$0.10 per share against an estimate of -$0.102
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.1071

CRDL news

  • Press releasePRNewswire

    Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

  • Press releasePRNewswire

    Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

  • Press releasePRNewswire

    Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

  • Press releasePRNewswire

    Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

  • Press releasePRNewswire

    Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

  • Press releasePRNewswire

    Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

  • Press releasePRNewswire

    Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.